118 results about "Pulmonary Cancers" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

The application discloses an antibody targeting DLL3 and application thereof, and relates to the field of biological medicines. Specific anti-DLL3 nanobodies are screened in the embodiment of the application, and a bispecific antibody constructed from the anti-human DLL3 nanobody or humanized nanobody and an anti-human CD3 antibody is prepared, the obtained bispecific antibody has good antitumor activity, can be applied to preparation of at least one drug for preventing or treating a DLL3 expression abnormality related tumor or cancer disease including small cell lung cancer, and has wide application.

The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

The application relates to the technical field of medicines, and discloses an application of homoharringtonine in the preparation of a medicine for treating small cell lung cancer, and further provides a medicine for treating small cell lung cancer and containing homoharringtonine. The application discloses an action mechanism of homoharringtonine, an active ingredient of traditional Chinese medicine, against SCLC, and discloses that the traditional Chinese medicine ingredient HHT inhibits a malignant phenotype by targeting tumor-specific glycosylation enzyme MGAT5, provides an innovative perspective of glyco-biology for the research of traditional Chinese medicine against tumors, provides an important scientific basis for the subsequent development and application of homoharringtonine, and provides a new medicine treatment approach for treating small cell lung cancer.

A method for improving the survival of a subject with cancer is disclosed, comprising applying an alternating electric field having a predetermined frequency and electric field intensity to a target site of the subject containing one or more cancer cells for a predetermined period of time, and administering the subject a therapeutically effective amount of a checkpoint inhibitor. A method for treating a subject with cancer is disclosed, comprising applying an alternating electric field having a predetermined frequency and electric field intensity to a target site of the subject containing one or more cancer cells for a predetermined period of time, and administering the subject a therapeutically effective amount of a checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is nivolumab, pembrolizumab, or atezolizumab. Furthermore, a method for improving the survival of a subject with non-small cell lung cancer is disclosed, comprising applying an alternating electric field having a predetermined frequency and electric field intensity to a target site of the subject containing one or more non-small cell lung cancer cells for a predetermined period of time, and administering the subject a therapeutically effective amount of a checkpoint inhibitor. A method for treating a subject having non-small cell lung cancer is disclosed, the method comprising applying an alternating electric field having a predetermined frequency and electric field intensity to a target site of the subject containing one or more non-small cell lung cancer cells for a predetermined period of time, and administering to the subject a therapeutically effective amount of a checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), semiprimab (brand name Ributayo), dostallimab (Jemperli), atezolizumab (Tecentriq), durvalumab (Imfinzi), or avelumab (Bavencio).

This invention relates to the field of biomedicine and discloses a composition for treating non-small cell lung cancer metastasis that targets replication stress vulnerability and its application. The composition includes a dual-responsive polymer prodrug, which consists of a block copolymer backbone, a matrix metalloproteinase cleavage peptide sequence coupled to the hydrophilic end, and an active molecular group coupled to the hydrophobic end based on an asymmetric grafting structure. The active molecular group comprises a replication stress inducer and an ATR kinase inhibitor. This invention maintains the amorphous phase of the micelle core through the asymmetric grafting structure, eliminating the permeation barrier caused by spontaneous crystallization of components. This amorphous core provides a proton permeation channel, ensuring the synchronous in-situ release of multiple target drugs, thereby blocking the DNA replication fork repair pathway and inducing mitotic catastrophe, maintaining the spatiotemporal overlap of multiple drug interventions in the pathological target area, and avoiding the risk of drug resistance.

Disclosed herein are methods of determining whether a subject suffering from non-small cell lung cancer (NSCLC) is sensitive to treatment with osimertinib. In some embodiments, the method comprises obtaining an experimental matrix comprising a mutation status of at least one gene in an experimental sample associated with the subject, applying the obtained experimental matrix to a model, the model being based on a partitioning matrix comprising, for a plurality of reference samples, a mutation status of at least one gene and a sensitivity label for each of the plurality of reference samples indicating whether a corresponding reference subject is sensitive to osimertinib, wherein the at least one gene of the partitioning matrix corresponds to the at least one gene of the experimental matrix, and determining the subject as sensitive to treatment with osimertinib based on a result of the applied model.

The invention relates to pharmaceutical compounds and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of the SMARCA2 protein and to its use in the treatment of SMARCA4 deficient cancers, e.g., SMARCA4 deficient non-small cell lung cancer (NSCLC).

Use of a quinazoline compound and a third-generation epidermal growth factor receptor (EGFR) inhibitor in a combined drug for treating non-small cell lung cancer. The quinazoline compound comprises at least one of a quinazoline derivative represented by formula (I), a salt thereof, a solvate thereof, a hydrate thereof, and a polymorph thereof.

Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

This invention discloses a novel class of β-carboline quaternary ammonium salt derivatives, their preparation methods, and applications. The derivatives have the structure shown in Formula I, where R1, R2, and R3 are various substituents, and X... ‑ It is a halide ion. Its preparation method uses substituted indole-2-methylamine and substituted α-haloacetophenone as starting materials, and constructs them through a one-step cyclization reaction in an aprotic solvent mediated by a catalytic protic acid (such as p-toluenesulfonic acid). This method is mild, simple to operate, requires no metal catalyst, eliminates the risk of metal residue, and has good functional group compatibility. Activity tests of the obtained series of compounds showed that they have significant inhibitory activity against the proliferation of non-small cell lung cancer cell lines (such as A549 and H1299), with some compounds exhibiting activity superior to the positive control drug cisplatin. Therefore, this compound has important application value in the preparation of antitumor drugs, especially anti-lung cancer drugs.

Disclosed are novel compounds for use in treating a proliferative disorder such as a cancer. Further disclosed are compositions comprising the novel compounds. Methods of using the disclosed compounds and compositions are further described. The methods include administering one or more of the disclosed compounds for treatment of various proliferative disorders, including an HRAS-driven cancer, a KRAS-driven cancer, a NRAS-driven cancer, Ewing sarcoma, B-cell acute lymphoblastic leukemia, leukemia, lung cancer, non-small cell lung cancer (NSCLC), solid tumor, breast cancer, triple-negative breast cancer (TNBC), hormone-resistant triple negative breast cancer. Further described are combination therapies in which a novel compound is administered in combination with one or more of a MEK inhibitor, a KRAS G12C inhibitor, or a Selective Estrogen Receptor Degrader (SERD) to an individual in need thereof.

The application belongs to the field of diagnosis and treatment, and particularly relates to a lung cancer EGFR mutation non-invasive prediction model based on unsupervised decoupling and gate fusion. A multi-modal fusion model is constructed based on enhanced CT images and clinical data of non-small cell lung cancer patients. The application adopts a mask image modeling task, and autonomously learns morphological and texture primitive features of tumors from three-dimensional enhanced CT images without EGFR mutation labels. The application overcomes the dependence on a large amount of labeled data, enables the model to learn visual representations with high discriminability and generalization ability from unlabeled data, and significantly improves feature expression capability. A multi-modal fusion architecture based on a gate mechanism is designed, which can dynamically adjust the contribution weights of deep features, imaging features and clinical information in different samples. Personalized feature fusion for different cases is realized, the limitations of traditional static fusion methods are overcome, and complementary information between multi-source heterogeneous data is fully mined.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to the application of a formula for nourishing vital energy and strengthening the body in reducing the toxicity of adjuvant chemotherapy after radical resection of non-small cell lung cancer. This invention discloses a formula for nourishing vital energy and strengthening the body, characterized in that it is composed of the following components by weight: 15-30 parts raw Astragalus membranaceus, 9-21 parts prepared Rehmannia glutinosa, 15-30 parts stir-fried Dioscorea opposita, 9-15 parts Atractylodes macrocephala, 9-15 parts Poria cocos, 15-30 parts raw Coix lacryma-jobi, 9-15 parts Ophiopogon japonicus, 9-15 parts Asparagus cochinchinensis, 15-30 parts Adenophora stricta, 9-15 parts Ligustrum lucidum, 9-15 parts Eclipta prostrata, 9-15 parts stir-fried germinated barley, 9-15 parts stir-fried malt, and 3-6 parts prepared Glycyrrhiza uralensis. This invention can restore vital energy, reverse postoperative weakness, build a foundation for chemotherapy tolerance to reduce toxic side effects, improve chemotherapy tolerance, reduce the risk of interruption to ensure efficacy, improve quality of life during chemotherapy, and help prolong postoperative survival.

The application relates to application of miRNA as a target point in preparation of a drug for treating non-small cell lung cancer, and belongs to the biomedical technology field. The application provides application of miR-423-5p or miR-135a-5p as a target point in preparation of a drug for treating non-small cell lung cancer, specifically, application of an expression inhibitor of miR-423-5p or an overexpression reagent of miR-135a-5p in preparation of a drug for treating non-small cell lung cancer. The expression inhibitor of miR-423-5p or the overexpression reagent of miR-135a-5p in the application can cause the proliferation and migration ability of representative cells A549 and NCI-H1703 of non-small cell lung cancer to decrease and promote the apoptosis of the cells, and combined treatment of tumor chemotherapy drugs cisplatin or carboplatin can enhance the growth inhibition on the above two cell lines.

The application discloses a non-small cell lung cancer auxiliary decision-making method based on multi-modal causal representation and belongs to the field of clinical auxiliary decision-making. The method comprises the following steps: S1, obtaining clinical texts of non-small cell lung cancer patients, inputting the texts into a text feature extraction network, and obtaining text features; S2, obtaining imaging examination data of the non-small cell lung cancer patients, inputting the data into an image feature extraction network, and obtaining image features; S3, obtaining genomic data of the non-small cell lung cancer patients, inputting the data into an omics feature extraction network, and obtaining gene features; S4, mapping and splicing the text features, the image features and the gene features to obtain mixed variable representation, inputting the mixed variable representation into a random causal relationship network, and combining a pessimistic estimation mechanism to generate an auxiliary decision. Through the introduction of long text analysis of rotary position coding, lesion image extraction of multi-order gating aggregation and gene pathway analysis of graph attention mechanism, efficient representation of multi-modal data is realized.

This invention discloses a semi-sandwich structured ruthenium triphenylphosphine dithiocarboxylic acid complex with a simple preparation process and its applications. The complex has the structure shown in Figure (I), with the central ruthenium and... η 5 - Coordination with cyclopentadiene, triphenylphosphine, and dithiocarboxylic acid derivatives, wherein the dithiocarboxylic acid ligands are selected from ethyl xanthic acid, isopropyl xanthic acid, ... N,N Diethyldithiocarbamic acid, morpholine dithiocarbamic acid, and carbazole dithiocarbamic acid. This invention employs a simple one-step method of room temperature preparation and recrystallization purification using a ruthenium precursor and dithiocarbamic acid ligand. This method offers advantages such as readily available raw materials, mild reaction conditions, simple post-processing, and high yield. In vitro tests show that the complexes exhibit excellent anti-proliferative activity against non-small cell lung cancer A549 cells, significantly superior to cisplatin. The complexes demonstrate activity by reducing mitochondrial membrane potential, inducing intracellular reactive oxygen species accumulation, and arresting the cell cycle (G1 phase), leading to late apoptosis in A549 cells.

The application discloses a 3'-deoxyadenosine compound and application thereof in preparation of an antitumor drug. The 3'-deoxyadenosine compound and the pharmaceutical composition thereof have good antitumor proliferation effect. Compared with a parent drug, the 3'-deoxyadenosine compound has better affinity to a cell membrane, so that the half-life of in-vivo metabolism of the drug is longer, and the drug stays in the body for a longer time. Compared with other nucleoside antitumor drugs, the cordycepin derivative and the pharmaceutical composition thereof have a wider range of tumor types and effects, including excellent inhibition effect on gastric cancer, pancreatic cancer, liver cancer, small cell lung cancer, colorectal cancer, melanoma, ovarian cancer and the like, and the side effect is lower and the curative effect is better.

The application provides an application of PPB in preparation of a drug for preventing or treating non-small cell lung cancer, and relates to the technical field of biological medicines. TRIM47 The CAS number of the PPB is 1415504-32-3. The PPB provided in the application can effectively inhibit the migration and activity of NCI-H1299 cells and SPC-A1 cells, two kinds of non-small cell lung cancer cells, thereby helping to provide a safer and more effective treatment scheme for non-small cell lung cancer treatment.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

The present application belongs to the tumor precision medicine and artificial intelligence medical technology field, and particularly relates to a non-small cell lung cancer neoadjuvant immunotherapy efficacy prediction method based on transfer learning. The method first pretreats the non-small cell lung cancer immunotherapy cohort and the neoadjuvant immunotherapy cohort, selects immunotherapy and neoadjuvant immunotherapy characteristic genes, and based thereon, carries out deep learning training on the immunotherapy cohort to obtain a basic model, finally, the basic model is fine-tuned to the neoadjuvant immunotherapy training data set through transfer learning, and finally used to the neoadjuvant immunotherapy cohort to predict the neoadjuvant immunotherapy effect. The present application improves the stability and generalization ability of the model in the small sample neoadjuvant treatment scene through gene selection and transfer fine-tuning, and can be used for clinical auxiliary decision and population stratification.

The present invention relates to gene editing agents (e.g., CRISPR / Cas) that target mutated oncogenes (e.g., a mutated oncogene a cancer is addicted to) and uses thereof (e.g., for inactivation of mutated oncogenes and / or treatment cancer). In some embodiments, the mutated oncogene is a mutated KRAS. In some embodiments, the cancer is pancreatic ductal adenocarcinoma, non-small cell lung cell, or colorectal cancer.

This invention belongs to the field of pharmaceutical formulation technology, specifically disclosing a gastrodin transdermal patch and its preparation method. The patch consists of a backing layer, a drug-containing matrix layer, and an anti-adhesive layer, using gastrodin as the active ingredient. It employs HP-β-CD inclusion technology, combined with an HPMC and PVP polymer backbone and an oleic acid-menthol composite transdermal enhancement system. The preparation utilizes solvent casting and low-temperature vacuum drying processes, which are mild and controllable. This invention effectively solves the problems of difficult transdermal absorption, easy recrystallization, and low bioavailability of gastrodin. The resulting patch has excellent adhesion, no skin irritation, high transdermal penetration, and good skin biocompatibility. It can efficiently cross the blood-brain barrier, regulate the neuroinflammatory microenvironment in the brain, significantly inhibit the colonization and progression of non-small cell lung cancer brain metastases, and strongly reverse tumor-related anxiety and depression-like mood disorders. It provides a novel drug delivery regimen with great clinical translational potential for the non-invasive synergistic treatment of brain tumors and their associated mood disorders.

The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).

The application discloses a lung cancer gene mutation prediction method based on unsupervised clustering double-stage attention multi-instance learning, and relates to the technical field of pathological image analysis and gene detection. H&E staining pathological whole section images of non-small cell lung cancer patients and corresponding gene mutation data are collected to construct a data set; the images are preprocessed by using the OTSU method, segmented into blocks and high-dimensional feature vectors are extracted; the block features are grouped into cluster feature sets through unsupervised clustering; a double-stage attention mechanism composed of intra-cluster and inter-cluster is used to hierarchically aggregate and generate global features; finally, a classification model is used to output mutation positive / negative prediction results. The application groups the features through unsupervised clustering and structures the features, combines double-stage attention to strengthen key information, does not need complex manual annotation, adapts to various driver gene mutation prediction requirements, effectively deals with tumor heterogeneity and feature sparsity, improves prediction accuracy and generalization ability, and provides low-cost and efficient targeted therapy preliminary screening technical support for clinics.

Described herein are combination therapies comprising engineered anti-IL-2 antibodies in combination with an immune checkpoint inhibitor such as avelumab and an initial low dose of IL-2 and related therapeutic methods for a subjects with cancer, including a solid tumor and specifically non-small cell lung cancer (NSCLC).

This disclosure provides a method for improving median progression-free survival (PFS) and overall survival in treatment-naive subjects or a treatment-naive population with EGFR-positive non-small cell lung cancer (NSCLC).